Citizens Reiterates Buy Rating on NRC with $23 Target
Citizens has reiterated its buy rating on NRC, maintaining a positive outlook with a $23 price target, a 18.84% upside from the current price.
Key Points
- Citizens analyst Constantine Davides reiterated a buy rating on NRC with a price target of $23 on June 22, 2026.
- Citizens's $23 price target implies 18.84% upside from NRC Health's ($NRC) current $19.35 share price.
- NRC shares were trading at $19.35 on Monday, reflecting interest from various institutional investors.
- Insiders at NRC have been actively buying shares, with notable purchases by executives in early 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Citizens analyst Constantine Davides has reiterated a buy rating on NRC, setting a price target of $23. This announcement was made on June 22, 2026, highlighting a positive outlook for the company. NRC shares were trading at $19.35 on Monday.
Other Institutional Activity in NRC
Kayne Anderson Rudnick Investment Management LLC reduced its holdings by 21,473 shares, leaving it with 2,636,355 shares valued at approximately $44.8 million. Morgan Stanley also trimmed its position by 1,829 shares, ending with 1,001,880 shares worth about $17 million. BlackRock, Inc. decreased its stake by 29,468 shares, holding 975,855 shares valued at $16.6 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 662,837 shares, valued at roughly $11.3 million. Geode Capital Management, LLC increased its stake by 10,336 shares, bringing its total to 393,847 shares worth about $6.7 million.
NRC Health Stock Down 11.4%
Shares of NRC traded near $19.35 on Monday. The company's stock has seen various institutional movements, reflecting ongoing interest. The 52-week range for NRC is not available, but the current trading price suggests a focus on the company's future potential.
$NRC price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at NRC Health
Insider activity at NRC has been notable with several executives buying shares. On March 12, 2026, Jason Russell Rau, Executive Vice President, purchased 60,000 shares. Shane Harrison, EVP & Chief Financial Officer, bought 8,000 shares at an average price of $12.27 on February 17, 2026. Additionally, Parul Bhandari and Stephen Lockhart each acquired 8,819 shares on January 22, 2026.
Analysts Set New Price Targets
On June 22, 2026, Citizens initiated a buy rating on NRC with a price target of $23, affirming confidence in the company's potential.
Bottom Line
The reiteration of a buy rating by Citizens, coupled with insider purchases, suggests optimism around NRC's future prospects. Institutional activities indicate varied interest levels, with some funds reducing and others increasing their positions. As always, it's important to remember that analyst ratings are projections and investors should consider their own research and risk tolerance.
Get NRC Health alerts
New 13F filings, insider trades, and analyst moves on $NRC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.